Browse Drug Recalls
2,085 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 2,085 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 2,085 FDA drug recalls in 2013.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| May 2, 2013 | Avastin 1.25 mg/0.05 mL Injectable, 4 mL vials, Compounded by The Compounding... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Mitomycin 0.3 mg/mL Injectable, 10 mL vials, compounded by The Compounding Sh... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Glutathione 200 mg/mL Injectable, 50 mL vials, compounded by The Compounding ... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Gentamicin Sulfate Injection USP 80 mg/2 mL(40 mg/mL as Gentamicin), 2 mL Sin... | Presence of Particulate Matter: visible particles were identified floating in the primary container. | Class II | Hospira Inc. |
| May 2, 2013 | Baclofen/Bupivacaine 2,000 mcg/20 mg/mL Injectable, 45 mL vial, Compounded by... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Ascorbic Acid 500 mg/mL Injectable, 100 mL and 500 mL vials, compounded by Th... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Dexpanthenol 200 mg/mL Injectable, 100 mL vial, compounded by The Compounding... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Methylcobalamin 1,000 mcg/mL Injectable, 50 mL vials, compounded by The Compo... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Baclofen 1,000 mcg/mL Injectable, 20 mL and 40 mL vial, Compounded by The Com... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Praziquantel 56.8 mg, 50 mL vial, compounded by The Compounding Shop, St. Pet... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Lipoic Acid 25 mg/mL Injectable, 100 mL vials, compounded by The Compounding ... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Betamethasone 6 mg/mL Injectable, 5 mL vial, compounded by The Compounding Sh... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Dexamethasone 10 mg/mL Injectable, 2 mL vial, compounded by The Compounding S... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Procaine 1% Injectable, 100 mL and 250 mL vials, compounded by The Compoundin... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Testosterone Cypionate 200 mg/mL Injectable, 10 mL vials, compounded by The C... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | MIC (Methionine, Inositol, and Choline) + B12 25/50/50mg/1000mcg/mL Injectabl... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Hydroxyprogesterone 250 mg/mL Injectable, 4 mL, 6 mL,8 mL and 10 mL vials, co... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Carnosine 5% Opth drop, 40 mL vial, compounded by The Compounding Shop, St. P... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Methotrexate 25mg/mL Injectable, 10 mL vials, Compounded by The Compounding S... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | MIC (Methionine, Inositol, and Choline) Injectable, 30 mL vials, compounded b... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 2, 2013 | Tri-Mix Injections in 5 mL and 10 mL vials (Alprostadil, Phentolamine and Pap... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | THE COMPOUNDING SHOP, INC. |
| May 1, 2013 | CLENZIderm M.D. Acne Therapeutic System Normal to Oily Skin kit, Distributed ... | cGMP Deviations; during the production process, CLENZIderm M.D. Daily Foam Cleanser was filled in... | Class II | Medicis Pharmaceutical Corp |
| May 1, 2013 | Velextra All-Natural Herbal Supplement, packaged in 1 & 2 capsule blister pac... | Marketed Without an Approved NDA/ANDA; products have been found to contain tadalafil, the active ... | Class I | Beamonstar Products |
| May 1, 2013 | SexVoltz All Natural Herbal Supplement, packaged in 1 & 2 capsule blister pac... | Marketed Without an Approved NDA/ANDA; products have been found to contain tadalafil, the active ... | Class I | Beamonstar Products |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 137 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 88 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 175 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | HydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 16 fl. oz. (473 mL)... | Subpotent; 24 month stability test station | Class III | Hi-Tech Pharmacal Co., Inc. |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 25 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | DOBUTamine in 5% Dextrose Injection, USP, 250 mg Total, 1000 mcg/mL 250 mL ba... | Lack of Assurance of Sterility: Confirmed report of leaking in the primary container. | Class II | Hospira Inc. |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 50 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Vicerex A Powerful And Fast Acting Male Sexual Enhancer, 10 capsules per box,... | Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined th... | Class I | American Lifestyle.Com |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 75 mcg, packaged in a) 100-count... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 30, 2013 | Black Ant, 4600 mg x 4. Product is packaged in a small green box with gold l... | Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined th... | Class I | American Lifestyle.Com |
| Apr 30, 2013 | Levoxyl (levothyroxine sodium) tablets, USP, 125 mcg, packaged in a) 100-coun... | Subpotent Drug: The products were below specification for potency at the expiry stability point. | Class II | King Legacy, a wholly owned subsidiary of Pfizer |
| Apr 26, 2013 | Amoxicillin for Oral Suspension, USP 400mg/5mL, NDC 0093-4161-78 (75ml) and 0... | Discoloration: This recall is being carried out due to a yellow to brown discolored Amoxicillin p... | Class III | Teva Pharmaceuticals USA, Inc. |
| Apr 24, 2013 | Cornea Coat, Hydroxypropylmethylcellulose, 1.5ml Syringe, Rx Only. Manufactu... | Marketed without an Approved NDA/ANDA. | Class II | Insight Instruments, Inc. |
| Apr 22, 2013 | Renacidin Irrigation: 1000 ml,1120ml Bladder Irrigation, 30 day expiration, | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
| Apr 22, 2013 | Papaverine Inj 30mg/ml Syr, 5mlsyr, 10mlsyr,10x0.95mlsyr Penile Injection, 9... | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
| Apr 22, 2013 | Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-0... | Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was f... | Class II | Mylan Pharmaceuticals Inc. |
| Apr 22, 2013 | Tobramycin Opth Soln 13mg/ml, 7ml Opthalmic Soln, 10 day expiration, | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
| Apr 22, 2013 | Trimix Inj 30:1:40 MDV, 5 ml Penile Injection, 30 and 90 day expiration, | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
| Apr 22, 2013 | Trimix Inj 30:3:5 MDV, 10ml Penile Injection, 90 day expiration, | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
| Apr 22, 2013 | PGE-1 Inj 10mcg/ml MDV, 5ml Penile Injection, 90 day expiration, | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
| Apr 22, 2013 | Trimix Inj 4.25ml Form MDV Penile Injection, 90 day expiration, | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
| Apr 22, 2013 | HCG Inj 500un/ml MDV, 5 ml Subcutaneous, 30 day expiration, | Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality co... | Class II | Nora Apothecary and Alternative Therapies, Inc. |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.